Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanqing Cai

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Nature|December 17, 2025
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetesLixin Guo, Bo Zhang, Xia Xue, et al.
Eclinicalmedicine|July 21, 2025
Efficacy and safety of narlumosbart, an anti-RANKL monoclonal antibody, in postmenopausal women with osteoporosis: a multi-center, randomized, double-blind, placebo- and active-controlled, phased II studyYue Chi, Yukun Li, Qun Cheng, et al.
Science Bulletin|January 19, 2023
Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)Linong Ji, Weihong Song, Hui Fang, et al.
Journal of Orthopaedic Translation|May 25, 2026
Efficacy of once-weekly teriparatide versus alendronate in Chinese postmenopausal osteoporosis: a randomised, open-label, active-controlled, 48-week, multicentre phase III studyJiemei Gu, Aijun Chao, Yanan Huo, et al.
Nature Medicine|May 13, 2022
Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trialDalong Zhu, Xiaoying Li, Jianhua Ma, et al.
Diabetologia|November 21, 2025
Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trialDalong Zhu, Jianhua Ma, Weimin Wang, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Nature|December 17, 2025
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetesLixin Guo, Bo Zhang, Xia Xue, et al.
Eclinicalmedicine|July 21, 2025
Efficacy and safety of narlumosbart, an anti-RANKL monoclonal antibody, in postmenopausal women with osteoporosis: a multi-center, randomized, double-blind, placebo- and active-controlled, phased II studyYue Chi, Yukun Li, Qun Cheng, et al.
Science Bulletin|January 19, 2023
Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)Linong Ji, Weihong Song, Hui Fang, et al.
Journal of Orthopaedic Translation|May 25, 2026
Efficacy of once-weekly teriparatide versus alendronate in Chinese postmenopausal osteoporosis: a randomised, open-label, active-controlled, 48-week, multicentre phase III studyJiemei Gu, Aijun Chao, Yanan Huo, et al.
Nature Medicine|May 13, 2022
Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trialDalong Zhu, Xiaoying Li, Jianhua Ma, et al.
Diabetologia|November 21, 2025
Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trialDalong Zhu, Jianhua Ma, Weimin Wang, et al.
Pageof 4